Dataset Information

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

ABSTRACT: This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients’ tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor’s particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

DISEASE(S): Recurrent Esophageal Carcinoma,Thyroid Neoplasms,Breast Carcinoma,Carcinoma,Recurrent Colon Carcinoma,Colon Carcinoma,Urinary Bladder Neoplasms,Endometrial Neoplasms,Recurrent Rectal Carcinoma,Breast Neoplasms,Neoplasms,Esophageal Neoplasms,Recurrent Breast Carcinoma,Carcinoma, Renal Cell,Stomach Neoplasms,Refractory Lymphoma,Multiple Myeloma,Kidney Neoplasms,Melanoma,Recurrent Uterine Corpus Cancer,Advanced Malignant Solid Neoplasm,Recurrent Head And Neck Carcinoma,Thyroid Diseases,Rectal Neoplasms,Skin Neoplasms,Recurrent Glioma,Recurrent Multiple Myeloma,Recurrent Bladder Carcinoma,Carcinoma, Hepatocellular,Uterine Corpus Cancer,Liver And Intrahepatic Bile Duct Carcinoma,Neoplasms, Plasma Cell,Malignant Uterine Neoplasm,Skin Carcinoma,Thyroid Gland Carcinoma,Recurrent Gastric Carcinoma,Recurrent Lymphoma,Cervical Carcinoma,Recurrent Thyroid Gland Carcinoma,Pancreatic Carcinoma,Lung Neoplasms,Colorectal Carcinoma,Prostatic Neoplasms,Recurrent Pancreatic Carcinoma,Gastric Carcinoma,Recurrent Malignant Solid Neoplasm,Ovarian Carcinoma,Recurrent Ovarian Carcinoma,Colorectal Neoplasms,Ovarian Neoplasms,Lung Carcinoma,Pancreatic Neoplasms,Recurrent Skin Carcinoma,Bladder Carcinoma,Recurrent Colorectal Carcinoma,Recurrent Lung Carcinoma,Refractory Multiple Myeloma,Recurrent Liver Carcinoma,Refractory Malignant Solid Neoplasm,Rectal Carcinoma,Lymphoma,Head And Neck Carcinoma,Uterine Neoplasms,Esophageal Carcinoma,Recurrent Cervical Carcinoma,Glioma,Recurrent Prostate Carcinoma,Prostate Carcinoma,Kidney Carcinoma,Carcinoma, Ovarian Epithelial,Recurrent Melanoma,Colonic Neoplasms,Endometrial Carcinoma

PROVIDER: 2191620 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:Lymphoplasmacytic lymphomas and marginal zone lymphomas of nodal, extra-nodal and splenic types account for 10% of non-Hodgkin lymphomas. They are similar at the cell differentiation level, sometimes making difficult to distinguish them from other indolent non-Hodgkin lymphomas. To better characterize their genetic basis, we performed array-based comparative genomic hybridization in 101 marginal zone lymphomas (46 MALT, 35 splenic and 20 nodal marginal zone lymphomas) and 13 lymphoplasmacytic lymphomas. Overall, 90.1% exhibited copy-number abnormalities. Lymphoplasmacytic lymphomas demonstrated the most complex karyotype (median=7 copy-number abnormalities), followed by MALT (4), nodal (3.5) and splenic marginal zone lymphomas (3). A comparative analysis exposed a group of copy-number abnormalities shared by several or all the entities with few disease-specific abnormalities. Gain of chromosomes 3, 12 and 18 and loss of 6q23-q24 (TNFAIP3) were identified in all entities. Losses of 13q14.3 (MIRN15A-MIRN16-1) and 17p13.3-p12 (TP53) were found in lymphoplasmacytic and splenic marginal zone lymphomas; loss of 11q21-q22 (ATM) in nodal, splenic marginal zone and lymphoplasmacytic lymphomas; loss of 7q32.1-q33 in MALT, splenic and lymphoplasmacytic lymphomas. Abnormalities affecting the NF-kB pathway were observed in 70% of MALT and lymphoplasmacytic lymphomas and 30% of splenic and nodal marginal zone lymphomas, suggesting distinct roles of this pathway in the pathogenesis/progression of these subtypes. Elucidation of the genetic alterations contributing to the pathogenesis of these lymphomas may guide to design specific therapeutic approaches. One hundred fourteen patients were included in this study: 46 MALT lymphomas (22 pulmonary, 11 salivary glands, 7 lacrimal glands and 6 gastrointestinal), 35 splenic marginal zone lymphomas, 20 nodal marginal zone lymphomas and 13 non-Waldenström’s Macroglobulinemia lymphoplasmacytic lymphomas. All cases were reviewed prior to study on paraffin sections with immunohistochemistry. Sections of each frozen tissue used for study were also reviewed by histological examination and immunohistochemistry before was submitted for the study.

Dataset Information

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure